Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04740827 · ClinicalTrials.gov registry record · Phase 3
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 315
- Enrollment target
NCT04740827 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 315 participants.
The verdict
NCT04740827, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 315 participants
- Enrollment target
Study Summary
This study will assess the safety, tolerability, and efficacy of Atogepant 60 mg compared with placebo in participants with episodic migraine and who have previously failed 2 to 4 classes of oral prophylactic treatments.
Interventions
- DRUG Placebo
- DRUG Atogepant 60 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2021-03-05 |
| Est. Completion | 2022-08-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04740827
The ClinicalTrials.gov registry entry for NCT04740827 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 315 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04740827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04740827 about?
NCT04740827 is a clinical study titled "Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.". This study will assess the safety, tolerability, and efficacy of Atogepant 60 mg compared with placebo in participants with episodic migraine and who have previously failed 2 to 4 classes of oral prophylactic treatments.
What is the current status of trial NCT04740827?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 315 participants. The study started on 2021-03-05. Estimated completion is 2022-08-04.
What interventions are being tested in trial NCT04740827?
The interventions under investigation include: Placebo (DRUG), Atogepant 60 mg (DRUG).
Who is sponsoring clinical trial NCT04740827?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.